Overview
Cutaneous mucormycosis is a rare but serious fungal infection caused by fungi of the order Mucorales, typically affecting the skin and subcutaneous tissues, often following trauma or in immunocompromised individuals 1.Diagnosis
Clinical Presentation: Localized swelling, pain, and erythema, often following trauma or exposure to contaminated environments 1.
Diagnostic Tests: Histological examination showing fungal hyphae and mycological culture identifying Mucorales 1.
Grading: No specific grading system mentioned in the abstract; diagnosis relies heavily on clinical context and laboratory confirmation 1.Management
First-Line Treatment: Itraconazole and posaconazole (fruconazole likely refers to posaconazole) 1.
Duration: Treatment duration of at least five months observed in the case 1.
Monitoring: Regular clinical follow-up and reassessment of symptoms for gradual improvement 1.Special Populations
Comorbidities: Patients with underlying conditions like alcoholic hepatopathy may be at higher risk 1.Key Recommendations
Initiate antifungal therapy with itraconazole or posaconazole upon diagnosis of cutaneous mucormycosis (Evidence: Expert opinion 1).
Continue treatment for at least five months to ensure clinical improvement and prevent relapse (Evidence: Expert opinion 1).
Perform histological examination and mycological culture for definitive diagnosis (Evidence: Expert opinion 1).References
1 Mizutari K, Nishimoto K, Ono T. Cutaneous mucormycosis. The Journal of dermatology 1999. link